 IRVINE, Calif., April 06, 2021 GLOBE NEWSWIRE -- ClearPoint Neuro, Inc. Nasdaq: CLPT the Company, a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates uniQure N.V. on the early completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase III clinical trial of AMT-130 being conducted in the United States for the treatment of early-stage Huntingtons disease. 